“Lower-than-approved doses of GLP-1 medications and isotretinoin (Accutane) are trending on social media. Yale Medicine experts discuss safety, effectiveness, and who may—or may not—be appropriate candidates.
Original story
Continue reading at Yale News
news.yale.edu
Summary generated from the RSS feed of Yale News. All article rights belong to the original publisher. Click through to read the full piece on news.yale.edu.
